Literature DB >> 33567198

Ustekinumab for Refractory Colitis Associated with Immune Checkpoint Inhibitors.

Anusha S Thomas1, Weijie Ma2, Yinghong Wang3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33567198     DOI： 10.1056/NEJMc2031717

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  10 in total

Review 1.  Facts and Hopes in Prediction, Diagnosis, and Treatment of Immune-Related Adverse Events.

Authors:  James W Smithy; David M Faleck; Michael A Postow
Journal:  Clin Cancer Res       Date:  2022-04-01       Impact factor: 13.801

Review 2.  Update on Immune Checkpoint Inhibitor Enterocolitis.

Authors:  Molly R Kelly-Goss; Yousef R Badran; Michael Dougan
Journal:  Curr Gastroenterol Rep       Date:  2022-10-20

Review 3.  Monitoring and Management of the Patient with Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis: Current Perspectives.

Authors:  Karmela K Chan; Anne R Bass
Journal:  J Inflamm Res       Date:  2022-05-25

4.  Ipilimumab and Nivolumab-Induced Colitis in a Patient With Recurrent Metastatic Melanoma.

Authors:  Hamid-Reza Moein; Brian Rutledge; Rafic Beydoun; Murray N Ehrinpreis
Journal:  Cureus       Date:  2021-04-11

Review 5.  Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition.

Authors:  Sonia Victoria Del Rincón; Wilson H Miller; Meagan-Helen Henderson Berg
Journal:  J Immunother Cancer       Date:  2022-01       Impact factor: 13.751

Review 6.  Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management.

Authors:  Liansha Tang; Jialing Wang; Nan Lin; Yuwen Zhou; Wenbo He; Jiyan Liu; Xuelei Ma
Journal:  Front Immunol       Date:  2021-12-21       Impact factor: 7.561

7.  Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study.

Authors:  Fangwen Zou; David Faleck; Anusha Thomas; Jessica Harris; Deepika Satish; Xuemei Wang; Aline Charabaty; Marc S Ernstoff; Isabella C Glitza Oliva; Stephen Hanauer; Jennifer McQuade; Michel Obeid; Amishi Shah; David M Richards; Elad Sharon; Jedd Wolchok; John Thompson; Yinghong Wang
Journal:  J Immunother Cancer       Date:  2021-11       Impact factor: 13.751

8.  COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis.

Authors:  Rikke Boedker Holmstroem; Ole Haagen Nielsen; Søren Jacobsen; Lene Buhl Riis; Susann Theile; Jacob Tveiten Bjerrum; Peter Vilmann; Julia Sidenius Johansen; Mogens Karsbøl Boisen; Rikke Helene Løvendahl Eefsen; Inge Marie Svane; Dorte Lisbet Nielsen; Inna Markovna Chen
Journal:  J Immunother Cancer       Date:  2022-09       Impact factor: 12.469

9.  Immune checkpoint inhibitor-related gastrointestinal toxicity in patients with malignancy involving the luminal gastrointestinal tract and its impact on cancer outcomes.

Authors:  Kevin Yu; Antony Mathew; Fiyinfoluwa Abraham; Rajan Amin; Miho Kono; Michael Overman; Dan Zhao; Anam Khan; Muhammad A Khan; Anusha S Thomas; Yinghong Wang
Journal:  Ann Gastroenterol       Date:  2022-07-30

10.  Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8 + T cells and an infiltration pattern that resembles ulcerative colitis.

Authors:  Sara Hone Lopez; Gursah Kats-Ugurlu; Remco J Renken; Henk J Buikema; Marco R de Groot; Marijn C Visschedijk; Gerard Dijkstra; Mathilde Jalving; Jacco J de Haan
Journal:  Virchows Arch       Date:  2021-08-02       Impact factor: 4.064
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.